Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigating the role of non-synonymous variant D67N of ADGRE2 in chronic myeloid leukemia.

BMC cancer - 5 Nov 2024

Afzal Ayesha, Jamshaid Harooma, Badshah Yasmin, Shabbir Maria, Trembley Janeen H, Zafar Sameen, Kamal Ghulam Murtaza, Afsar Tayyaba, Husain Fohad Mabood, Razak Suhail

Abstract excerpt

BACKGROUND: Chronic myeloid leukaemia (CML) is a type of blood cancer that begins in the hematopoietic stem cells. It is primarily characterized by a specific chromosomal aberration, the Philadelphia chromosome. While the fusion gene is a major contributor to CML, several other genes including ADGRE2, that are reported as highly expressed in hematopoietic stem cells and could be utilized as a therapeutic marker...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Predisposition to Disease
Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymorphism, Single Nucleotide

Share to Receptors, G-Protein-Coupled

Source

Open in PubMed Open full text

Identifiers

PMID: 39501172
DOI: 10.1186/s12885-024-13108-6
PMCID: PMC11536965

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigating the role of non-synonymous variant D67N of ADGRE2 in chronic myeloid leukemia.PMID 39501172Read ↗

Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing.Semantic proximity Read ↗

Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia.Semantic proximity Read ↗

Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing.Semantic proximity Read ↗

Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targetsSemantic proximity Read ↗

In Silico Genetics Revealing Novel Mutations in <i>CEBPA</i> Gene Associated with Acute Myeloid LeukemiaSemantic proximity Read ↗

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.Semantic proximity Read ↗

Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Integrating Human Genetics and Protective Genome Editing to Enable ADGRE2-Directed AML TherapySemantic proximity Read ↗

Identification of a novel gene fusion RNF213-SLC26A11 in chronic myeloid leukemia by RNA-SeqSemantic proximity Read ↗

Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.Semantic proximity Read ↗

ERCC6L2-related disease: a novel entity of bone marrow failure disorder with high risk of clonal evolutionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.